Quantcast
Last updated on April 24, 2014 at 11:09 EDT

Latest Proteasome inhibitor Stories

2011-01-31 15:11:00

EMERYVILLE, Calif., Jan. 31, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or...

2011-01-04 15:00:00

EMERYVILLE, Calif., Jan. 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and download...

2010-12-07 08:12:00

In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the sixth paragraph, first sentence, should read "In a subset analysis of patients who were refractory to bortezomib in their last line of therapy (n=128), carfilzomib achieved an ORR of 19 percent and CBR of 31 percent" rather than " In a subset analysis of patients who were...

2010-12-07 06:30:00

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after...

2010-12-06 15:00:00

EMERYVILLE, Calif., Dec. 6, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast. Investigators will discuss data presentations surrounding carfilzomib in multiple myeloma, as featured at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The virtual event will begin at 10:00 a.m. ET on December 7, 2010. The live webcast will be available at:...

2010-11-18 15:30:00

EMERYVILLE, Calif., Nov. 18, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, 2010 - 10:00 a.m. ET Investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The teleconference will begin at 10:00 a.m....

2010-11-10 15:00:00

EMERYVILLE, Calif., Nov. 10, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010 at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to...

2010-11-04 15:00:00

EMERYVILLE, Calif., Nov. 4, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Credit Suisse 2010 Healthcare Conference on Thursday, November 11, 2010 at 9:00 a.m. Mountain Time (8:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and download any...

2010-11-04 01:11:55

Proteasome inhibitor reduces inflammation and promotes bone healing in arthritis models A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting...

2010-10-26 15:00:00

EMERYVILLE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss third quarter 2010 financial results, on Wednesday, November 3, 2010, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2010 will be released earlier that day. Interested parties may access a...